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Law is an important component of the regulation of the use of 
the human body or body parts, new medical developments, and 
research on human subjects. Complex moral, ethical and public 
policy considerations must often be balanced when determining 
the boundaries between academic freedom, promoting public 
health, and protecting patients and research participants. Despite 
the implications of revolutionary scientific developments, the South 
African parliament has struggled to create a principled framework for 
biomedicine and research. 
Blood, blood products, tissues and gametes were, until 1 March 
2012, regulated by the Human Tissues Act.1 This old Act was hopelessly 
inadequate to deal with many innovations such as pre-implantation 
diagnosis.2 To address this vacuum, parliament passed the National 
Health Act in 2003,3 and implemented most of it in 2005.4 The 
outstanding parts of chapter 8, dealing with blood, blood products, 
tissues and gametes, were operationalised this year,5 and accompanying 
Regulations were published in the Government Gazette.6 
There was little legal regulation of health research until the 
National Health Act,3 which created a comprehensive, national 
ethical-legal framework. Like chapter 8, only parts of chapter 9 on 
health research and information were implemented in 2005,4 and 
the rest came into operation on 1 March 2012.5 However, unlike 
the provisions on blood, blood products, tissues and gametes, no 
regulations have been published to guide the implementation of the 
section on research with human subjects.
Regulation of blood, blood products, 
tissues and gametes in humans
Chapter 8 of the National Health Act3 and its accompanying 
Regulations6 create a comprehensive new framework for regulating, 
among others, the removal and use of blood, blood products 
and gametes from both living and dead persons. In this issue7 
McQuoid-Mason points out that the new provisions have widespread 
implications for doctors assisting patients or their relatives with 
tissue donations, organ transplants and donations of human bodies 
or tissues, revocations of donations, and confidentiality regarding 
such donations. Pepper8 also notes that the reforms introduced by 
the operationalisation of chapter 8 are a welcome step towards ‘partial 
relief from the regulatory vacuum’; although the new framework is 
imperfect, it is workable. McQuoid-Mason7 argues that this is partly 
due to the Regulations dealing with some issues not addressed by the 
National Health Act, e.g. they deal with recent concerns regarding the 
unlawful sale of kidneys to foreign patients, by prohibiting transplants 
into non-South African citizens unless ministerial permission is 
obtained. However, gaps remain in the reformed framework, and 
inaccuracies in the Regulations create new complexities.8 An example 
is the definition of transgenic cells in the Regulations,9 which are 
described as ‘cells derived from a species other than human’ – this is 
incorrect, as cells derived from other species are termed ‘xenogeneic’.
Sadly, the above means that despite this law reform being less than 
6 months old, it already lags behind medical advances. Furthermore, 
the gap between the law and science will widen further as new 
advances challenge the limited framework. Pepper therefore calls for 
reform of the National Health Act and its accompanying Regulations.8
The new framework for the regulation 
of health research with human subjects
The implementation of parts of chapter 9 of the National Health Act 
in 20054 heralded a new era in research regulation in South Africa. 
These created procedural protections for research participants, such as 
requiring ethical approval for all forms of health research, and giving 
the National Health Research Ethics Council the authority to issue 
ethical guidelines. Although this framework was welcomed, there 
have also been criticisms of it. In this issue Britz and Le Roux-Kemp10 
identify key shortcomings in the national ethical guidelines regulating 
informed consent to participation in clinical trials and call for these to 
be revised, updated, and aligned with international guidance.
The operationalisation of section 71 of the National Health Act 
on 1 March 2012 has completed our ethical-legal framework by 
introducing substantive legal norms on how health research with 
human subjects should be undertaken, providing inter alia that 
research may only be undertaken if: (i) it is done in the prescribed 
manner; (ii) written consent is obtained; (iii) it can be shown that 
therapeutic research involving minors is in their best interests; 
(iv) ministerial consent is obtained for non-therapeutic research 
involving minors; and (v) consent is obtained from parents or 
legal guardians for all research involving minors.3 However, no 
regulations have been published providing detail on, for example, 
how to obtain ministerial consent for non-therapeutic research 
involving minors.
Operationalising section 71 of the National Health Act has resulted 
in the law lagging behind science in terms of its conceptualisation 
of when and how human subjects should participate in health 
research, and has also strangled innovation. For example, Karim et 
al. have set out the public health arguments for why it is urgent that 
adolescents participate in research towards developing new HIV-
prevention technologies.11 However, given the restrictive framework 
created by section 71, such studies will be difficult to undertake, as 
it is unclear, for example, how ministerial consent will be obtained. 
There is also a disparate impact on social science studies, as the new 
framework prohibits independent consent by minors and limits the 
authority to provide proxy consent to parents or legal guardians. The 
administrative burden of obtaining ministerial consent for low- or 
no-risk studies may also limit their feasibility.12
Regulations on how to implement section 71 are urgently needed. 
In the longer term, law reform is required which creates an enabling 
environment that facilitates appropriate research and adequately 
protects research participants. 
The implementation of the final aspects of the National Health Act 
should  be good news – however, it isn’t, as the Minister of Health has 
ushered in a new legal framework that already lags behind scientific 
developments, and is strangling much-needed innovation in health. 
Political commitment is required to look to the future and ensure that 
there is synergy between unfolding scientific developments, public 
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